Steve Quake

It's very self-reinforcing.

Yeah, I mean, I can say something first.

Charlotte, if you've got thoughts, I'm curious to hear them.

So I do think AI approaches are going to be very useful designing molecules.

And so from the perspective of designing new therapeutics, whether they're small molecules or antibodies, yeah, I mean, there's a ton of investment in that area.

That is like a near-term fruit, perfect thing for venture people to invest in.

And there's opportunity there.

There's been enough proof of principle.

However, I do agree with you that if you want to really understand what happens when you drug a target, you're going to want to have some model of the cell and maybe not just the cell, but all the different cell types of the body to understand where toxicity will come from.

If you have on target toxicity and whether you get efficacy on the thing you're trying to do.

And so.

We really hope that people will use the virtual cell models we're going to build as part of the drug discovery development process.

And we would think it's going to, you know, I agree with you in a little bit blind spot.

And we think if we make something useful, people will be using it.

The other thing I'll say on that point is I'm very enthusiastic about the future of cellular therapies.

And one of our big bets at CZI has been starting the New York Biohub, which is aimed at really being very ambitious about establishing the engineering and scientific foundations of how to engineer completely radically more powerful cellular therapies.

And the virtual cell is going to help them do that.

It's going to be essential for them to achieve that mission.

Charlotte, you want to take a first pass at that and then I can say something?

So what can we do with a single cell?